Steve Worland, Ph.D., is CEO of Numerion Labs, where he leads efforts to transform drug discovery through AI and molecular science. With over three decades of experience spanning biotech leadership and therapeutic innovation, he has guided teams from early discovery to approved medicines, including contributions to Paxlovid® and Inlyta®. A scientist by training and entrepreneur by practice, Steve co-founded eFFECTOR Therapeutics and previously led Anadys Pharmaceuticals through its acquisition by Roche. He holds a Ph.D. in Chemistry from UC Berkeley and completed postdoctoral research at Harvard. He currently serves on the Board of Blacksmith Medicines and advises emerging biotech ventures.